e-learning
resources
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Assessing usability of QIAreach QuantiFERON-TB platform in a high tuberculosis prevalence, low-resource setting
Conceptor Kaaba, Maria Ruperez, Barry Kosloff, Nduku Ndunda, Kwame Shanaube, Helen Ayles
Source:
ERJ Open Res, 7 (4) 00511-2021; 10.1183/23120541.00511-2021
Journal Issue:
October
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Conceptor Kaaba, Maria Ruperez, Barry Kosloff, Nduku Ndunda, Kwame Shanaube, Helen Ayles. Assessing usability of QIAreach QuantiFERON-TB platform in a high tuberculosis prevalence, low-resource setting. ERJ Open Res, 7 (4) 00511-2021; 10.1183/23120541.00511-2021
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Low real-world utility of IGRA when screening for LTBI in a low incidence setting
Source: International Congress 2015 – Screening strategies in TB
Year: 2015
Programmatic experience with QuantiFERON-TB gold in-tube assay for contact screening in congregate settings in Singapore
Source: Annual Congress 2008 - New tests and methods to diagnose tuberculosis infection and disease and to monitor treatment
Year: 2008
Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting?
Source: Eur Respir J 2012; 40: 161-168
Year: 2012
The prevalence of latent tuberculosis infection in a children social center: Comparison of QuantiFERON-TB Gold with tuberculin skin testing
Source: Annual Congress 2010 - Tuberculosis in children
Year: 2010
How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries?
Source: Eur Respir J 2015; 45: 549-554
Year: 2015
Role of the QuantiFERON®-TB Gold In-Tube assay in screening new immigrants for tuberculosis infection
Source: Eur Respir J 2012; 40: 1443-1449
Year: 2012
Screening healthcare workers for Mycobacterium TB: Is QFT-G now the test of choice?
Source: Annual Congress 2012 - Abestosis, silicosis and hypersensitivity pneumonitis
Year: 2012
Evaluation of latent tuberculosis infection in health care workers by QuantiFERON-TB Gold test and tuberculin skin test
Source: Annual Congress 2011 - Risk assessment for tuberculosis
Year: 2011
Interferon release does not add discriminatory value to smear-negative HIV–tuberculosis algorithms
Source: Eur Respir J 2011; 39: 163-171
Year: 2012
Interferon release does not add discriminatory value to smear-negative HIV–tuberculosis algorithms
Source: Eur Respir J 2012; 39: 163-171
Year: 2012
IP-10 point-of-care tests for monitoring treatment efficacy in tuberculosis in a low-resource setting
Source: International Congress 2017 – Update on TB: latest news
Year: 2017
Comparison of the QuantiFERON-TB and tuberculin skin test for detection of latent tuberculosis infection in cancer patients in a developing country
Source: ERJ Open Res, 5 (4) 00258-2018; 10.1183/23120541.00258-2018
Year: 2019
IGRA testing to diagnose TB disease and infection. What is new in clinical practice and for programmatic management
Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination
Year: 2012
A comparison of QuantiFERON-TB Gold In-Tube test and new QuantiFERON-Microtube assay in children suspect of active TB and adults with active TB
Source: Annual Congress 2011 - Tuberculosis in pregnancy and childhood
Year: 2011
Usefulness of a daignostic method of tuberculosis infection, QuantiFERON TB-2G, in a contact investigation of medical staffs
Source: Eur Respir J 2006; 28: Suppl. 50, 139s
Year: 2006
The effect of the introduction of IGRA in screening French healthcare workers for tuberculosis
Source: Annual Congress 2012 - Tuberculosis: epidemiological and public health features
Year: 2012
Prevalence of LTBI using IGRA and TST in a cohort of health professional trainees from India
Source: Annual Congress 2011 - Risk assessment for tuberculosis
Year: 2011
Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India
Source: Eur Respir J 2014; 44: 1090-1093
Year: 2014
QuantiFERON-TB® Gold Plus as a potential tuberculosis treatment monitoring tool
Source: Eur Respir J , 49 (3) 1601976; DOI: 10.1183/13993003.01976-2016
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept